US Patent

US9802973 — Crystalline forms of ferric maltol

Method of Use · Assigned to Shield Tx UK Ltd · Expires 2035-10-23 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.

USPTO Abstract

There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2603 — Accrufer

Patent Metadata

Patent number
US9802973
Jurisdiction
US
Classification
Method of Use
Expires
2035-10-23
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Shield Tx UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.